CONTROLLED CLINICAL TRIAL (PT)
\kəntɹˈə͡ʊld klˈɪnɪkə͡l tɹˈa͡ɪə͡l pˌiːtˈiː], \kəntɹˈəʊld klˈɪnɪkəl tɹˈaɪəl pˌiːtˈiː], \k_ə_n_t_ɹ_ˈəʊ_l_d k_l_ˈɪ_n_ɪ_k_əl t_ɹ_ˈaɪ_əl__ p_ˌiː_t_ˈiː]\
Sort: Oldest first
-
A clinical trial involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicine, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trial is characterized as a RANDOMIZED CONTROLLED TRIAL [PUBLICATION TYPE]. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes are simply designated as controlled clinical trials.
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.